Barclays analyst Andrew Mok CFA maintains $CVS Health (CVS.US)$ with a buy rating, and adjusts the target price from $82 to $75.
According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $CVS Health (CVS.US)$'s main analysts recently are as follows:
The firm has adjusted its future earnings projections for CVS Health downwards, while considering the trajectory of the company's potential recovery.
The expectation is that the medical loss ratio trends for CVS Health will likely see improvement by 2025, influenced by the onset of start payments. However, there's an anticipation that the MLR will stay higher than the 2023 baselines for the time being.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
